The American Journal of Managed Care1mon
FDA Approves Ranibizumab Implant in Treatment of DME
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
Business Wire1mon
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab ...
Ophthalmology Times7d
PDS implant matches monthly injections in efficacy in DME treatment
In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...
Medscape24d
Finding the Optimal Treatment Plan for Exudative AMD
In this study, 4300 patients received 0.3 or 0.5 mg of ranibizumab every 3 months after the initial series of three monthly injections. After the first 3 injections the mean visual acuity improved ...
Nasdaq1mon
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...